Logo American Journal of Case Reports

Call: 1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Contact Us

Logo American Journal of Case Reports Logo American Journal of Case Reports Logo American Journal of Case Reports

10 January 2025: Articles  Indonesia

Pregnancy Complicated by Rapidly Progressing Vulvar Melanoma: A Case Study

Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Rare disease

Bagas Satriyo Wicaksono ORCID logo1ABEF*, Aditiyono Aditiyono ORCID logo2ABD, Dina Marlina ORCID logo1ABEF, Aditya Utomo ORCID logo1ABEF, Putri Nadhira Adinda Adriansyah ORCID logo3BEF, Dody Novrial ORCID logo4BCD

DOI: 10.12659/AJCR.944972

Am J Case Rep 2025; 26:e944972

0 Comments

Abstract

0:00

BACKGROUND: Vulvar melanoma during pregnancy is exceptionally rare. Hormonal and immunological changes in pregnancy have raised concerns about the potential for accelerated melanoma progression and poorer maternal outcomes. This case report describes an unusual presentation of vulvar melanoma in a pregnant patient, which rapidly progressed despite previous treatments, but resulted in a favorable fetal outcome.

CASE REPORT: A 40-year-old G3P2A0 woman at 28 weeks of gestation, with a history of vulvar malignant melanoma diagnosed 3 years prior, presented with sudden abdominal pain and hematuria. She had previously received 6 courses of chemotherapy. Physical examination revealed a 3-cm mass in the right vulva, while ultrasonography detected a hyperechoic solid mass in the cervix and elevated LDH levels. Given the advanced disease, the medical team proceeded with a cesarean hysterectomy, colpotomy for uterine corpus involvement, and bladder repair due to an iatrogenic laceration. Histopathological findings confirmed metastatic vulvar melanoma in the cervix and uterine corpus. The pregnancy was terminated at 27 weeks due to the progression of grade IV melanoma, but the neonate was delivered in stable condition. Unfortunately, the patient died 1 month after the operation.

CONCLUSIONS: This case underscores the potential for aggressive melanoma progression during pregnancy, likely exacerbated by physiological changes, yet highlights a successful fetal outcome. While chemotherapy can adversely affect the reproductive system and may lead to infertility, this patient was able to conceive, and the case illustrates the complex interplay of pregnancy and cancer progression.

Keywords: Case Management, Chemotherapy, Adjuvant, Melanoma, Melanoma, Cutaneous Malignant, Pregnancy Complications, Neoplastic, Vulvar Neoplasms

Introduction

Vulvar cancer is an uncommon disease that affects the female genital tract and accounts for only 5% of all gynecological cancers. The prevalence of invasive vulvar cancer sharply rises after the age of 50 years and reaches its highest point between the ages of 65 and 70 years [1]. Vulvar melanoma is a rare gynecological condition, accounting for only 2-10% of all vulvar malignancies [2]. Vulvar melanoma is the second most prevalent type of malignant tumor of the vulva, following vulvar squamous cell carcinoma (VSCC) [3]. Vulvar melanoma typically affects White women aged 50–70 years [4].

Pregnancy-associated cancer occurs in approximately 1 in 1000 pregnancies, and its incidence is rising [5]. Melanoma is one of the cancers that can affect women of reproductive age, with about 35% of women diagnosed in their childbearing years. Melanomas are generally categorized as cutaneous or mucocutaneous, with the latter, including genital melanoma, exhibiting a higher likelihood of recurrence and a poorer prognosis than cutaneous forms [6].

While cutaneous melanoma has a relatively favorable prognosis, with a 91% 5-year survival rate in females [7], mucocutaneous melanoma has a significantly lower 5-year survival rate of 47% [8,9]. Vulvar melanoma is an exceptionally rare subtype, especially during pregnancy, with only 5 cases documented in the literature since 1946 [10–13]. This type of melanoma often carries a poor prognosis due to its high metastatic potential and delayed diagnosis, and it is usually found in postmenopausal women aged 50–70 [13]. Symptoms, which often appear in advanced stages, can include itching, bleeding, abnormal discharge, and a palpable lump. The rarity of vulvar melanoma in pregnancy highlights the importance of awareness and early detection to improve outcomes [2].

Melanomas that develop during pregnancy pose distinctive problems due to difficulties in diagnosis as well as concerns regarding treatment and prognosis. There has been persistent concern that hormonal and immunological changes during pregnancy could negatively impact the progression of melanoma and lead to poorer outcomes [14]. Vulvar malignant melanoma has an unfavorable prognosis, primarily because of the tumor’s biological aggressiveness, hidden nature, lack of early symptoms, thin dermis, delayed discovery, and limited surgical options [14]. Many organizations recommend that women should delay pregnancy for 6–12 months after completing chemotherapy to allow for recovery and avoid conceiving with an oocyte growing during treatment. Chemotherapy can harm oocytes involved in ovulation owing to its effect on rapidly proliferating cells, leading to increased chances of miscarriage and birth abnormalities in pregnancies conceived shortly after treatment [15]. We present a rare case of a successful pregnancy in a 40-year-old woman who had undergone chemotherapy 6 months before conception and experienced aggressive metastasis before and during pregnancy. This case report describes a rare case of melanoma with rapid progression in pregnancy with favorable fetal outcomes and a literature review of the best current recommendations for vulvar melanoma in pregnancy.

Case Report

A 40-year-old G3P2A0 woman, at 6.5 months of gestational age (January 2024), with a history of recurrent vulvar melanoma before pregnancy came to the delivery room of our hospital (referral tertiary hospital) with labor pain 12 hours before admission; the labor pain was getting more frequent, with dysuria for 3 days before admission, urinary hesitancy, and hematuria. The patient also presented with a vulvar mass upon admission.

Figure 1 shows a timeline of the patient’s medical history. She had had a lump in the birth canal since 2020, which was painful and bled easily. She had no history of cervical cancer screening or abnormal skin lesions. Due to her concern about this lump, she went to an obstetrician, underwent a biopsy excision operation, and was administered multivitamin, albumin, and an immunomodulator. The biopsy results in 2020 were consistent with malignant vulvar melanoma. In 2021, a discolored vulvar mass reappeared, and the patient underwent a second excision biopsy at a secondary hospital. Biopsy results in 2021 were consistent with malignant vulvar melanoma. Imaging was not conducted because of limited facilities. The patient was scheduled for chemotherapy but did not attend a follow-up visit. The patient remained lost to follow-up for 1 year. In 2022, she went to a surgeon for a second opinion and then underwent a third biopsy.

Histopathological examination performed in 2022 revealed vulvar melanoma and invasion of the cervix. The patient was classified as having a stage III vulvar melanoma. She was then referred to a tertiary hospital and received chemotherapy (paclitaxel-carboplatin) at a referral tertiary hospital for a total of 6 cycles of neoadjuvant chemotherapy. The dosage administered was paclitaxel 175 mg/m2 IV followed by carboplatin AUC 5-6 IV day 1, repeated every 21 days for 3–6 cycles, and concluded in January 2023. The histopathological result in January 2023 after pathological biopsy during the follow-up post-chemotherapy was consistent with malignant melanoma of the vulva. Figure 2 shows the biopsy specimens of the patient throughout the study period. Chest radiography revealed no intrapulmonary metastasis. Magnetic resonance imaging (MRI) was not performed in the secondary hospital because of the cost to the patient.

On July 2023, she underwent a positive pregnancy check. No concerns were reported between February and November 2023. Previously, she had delivered twice, in 2004 and 2005.

The interval between the second pregnancy and appearance of the vulvar mass was 15 years. Throughout the pregnancy, she underwent prenatal treatment on 4 occasions, with 2 visits to a midwife, 1 visit to the primary healthcare center, and 1 visit to an obstetrician. She underwent antenatal care at the fetal clinic and the fetus was considered healthy. A previous antenatal examination revealed that the pregnancy had no complications.

On December 18, 2023, she reported experiencing hemorrhage from the birth canal. Consequently, she underwent conservative treatment for 2 days at a secondary hospital and was administered medication to promote fetal lung maturation. On December 27, 2023, she reported a recurrence of bleeding from the birth canal and thus received conservative treatment at the referral hospital for 4 days. Her blood pressure was 150/90 mmHg during conservative management, but she did not report any symptoms of headache, upper abdominal pain, or blurred vision. The results of an emergency ultrasonography examination on December 27, 2023, showed a single live intrauterine fetus at 27 weeks of gestation (Figure 3). There were no abnormalities in the fetus, but a 13.24×11.92×10.29 cm hyperechoic solid mass was found in the cervical region (Figure 3). The urinalysis test indicated +3 proteinuria. A diagnosis of severe preeclampsia was established, and the patient was managed according to the national preeclampsia protocol in Indonesia, receiving magnesium sulfate (MgSO4) and methyldopa 2×500 mg as antihypertensive therapy. She was discharged with a stabilized blood pressure of 110/80 mmHg.

Physical examination on admission revealed that she was in a state of full consciousness with normal vital signs. Abdominal examination revealed a uterine fundal height of 25 cm, with no observed contractions, and a fetal heart rate (FHR) ranging from 148 to 152 beats per minute. Genital examination revealed a 3×3 cm exophytic pigmented mass located on the outer vaginal wall (labia majora and minora). The lesion presented with irregular borders and heterogeneous pigmentation, suggestive of malignancy. The mass was accompanied by localized tenderness, raising concerns about the inflammatory response or nerve involvement (Figure 4). No other skin lesions were noted. Internal examination revealed the portio was thick, rigid, and posterior, without dilation. A urinary catheter was inserted, making the urine appear red.

Ultrasonography was performed upon admission. During the urinary bladder examination, the catheter balloon was visible. A dense mass, measuring 14.78×11.34×12.98 cm, was observed in the cervical region (Figure 5). Laboratory examination on February 1, 2024, at the tertiary care center showed an increased lactate dehydrogenase (LDH) level of 471. Preoperative hematology results showed an Hb level of 10 g/dL. Other laboratory results were within normal limits. The patient was diagnosed with suspected stage IV vulvar melanoma (T3NXM1) with high LDH levels.

She underwent surgery, transperitoneal cesarean section, and removal of the uterus and surrounding tissues (type IV radical hysterectomy). We decided to perform cesarean section for the baby due to progression of carcinoma to the uterine corpus, and preeclampsia, which constituted an obstetric indication for pregnancy termination (ICD code: O99.8, O99.2, O.82). Cesarean hysterectomy was performed.

An incision was made in the vaginal wall to access and remove the mass from the uterine corpus (colpotomy due to uterine corpus mass). Lastly, repair was performed on the urinary bladder to fix a tear caused by medical intervention (urinary bladder repair due to iatrogenic laceration). The documentation of the surgical findings is shown in Figure 6.

The procedure was performed under general anesthesia. A female infant was delivered, weighing 1000 grams, with a length of 35 cm, head circumference of 26 cm, and chest circumference of 23 cm. The Apgar score at 1’/3’/5’ was 6/7/8. A thorough investigation revealed the presence of a necrotic tumor measuring 15×10×5 cm. The tumor exhibited an irregular texture and infiltrated the uterus and the cervix. Furthermore, the cancer had formed adhesions with the omentum and the urinary bladder. A type IV hysterectomy was performed, resulting in total removal of the uterus.

Histopathological examination revealed metastasis of the melanoma to the urinary uterine corpus and cervix (Figure 7). There was ±2500 cc blood loss. The patient received 2 units of packed red blood cells during the surgery. The surgery was successful, without any notable complications. The patient received postoperative symptomatic medication (analgesics and antibiotics). Postoperative laboratory results showed Hb levels within normal limits, with a value of 10.8 g/dL.

During the observation period, the infant was treated in the Neonatal Intensive Care Unit (NICU) for 7 days and intubated with continuous positive airway pressure (CPAP) for respiratory assistance. The infant received care in a level 3 perinatology unit and was discharged in a satisfactory condition after 14 days of monitoring. Three months after the cesarean section, the infant was admitted for routine control. The latest reported condition of the baby was good with no developmental delay. No significant concerns were reported during the follow-up period. At the 3-month follow-up, the infant’s weight was 4970 g, length 59 cm, and head circumference 35 cm, but still required frequent monitoring for catch-up growth.

After the surgery, the patient was discharged upon request. She was scheduled to undergo chemotherapy following the surgery, but she did not attend the postoperative follow-up at 1 week. Unfortunately, after 1 month, the patient was admitted to the hospital because of difficulty in eating and anuria. Laboratory results during this admission showed hypoalbuminemia (0.89) and electrolyte imbalance (hyponatremia 133; hyperkalemia 5.12; and hypocalcemia 6.8). The patient underwent electrolyte and albumin correction to improve the overall condition. The condition of the patient deteriorated, and she died 1 month after the surgery.

Discussion

Melanomas during pregnancy present unique diagnostic and therapeutic challenges. Concerns about hormonal and immunological changes affecting melanoma progression are longstanding [13]. Vulvar melanoma is particularly aggressive, often with delayed diagnosis due to its concealed presentation and lack of early symptoms [16]. In our case, the patient had no prior concerns after chemotherapy, but experienced recurrence at 27 weeks of gestation, a period when tumor progression can accelerate due to pregnancy-related changes. The recurrence of symptoms highlights the rapid progression of vulvar melanoma in pregnancy, which is further complicated by hormonal and immune system shifts [14].

Despite limited data, our case resulted in a preterm live birth following a cesarean section due to the progression of vulvar carcinoma. Only a few cases of vulvar melanoma in pregnancy have been reported, emphasizing the rarity of the condition [10–13].

In our case, the patient did report any concerns prior to pregnancy after the completion of chemotherapy. However, symptoms recurred during her admission in the 27th week of gestation. The observation in this case indicates that the progression of incomplete vulvar melanoma during pregnancy occurs rapidly as the fetus grows. The highest incidence of vulvar melanoma is in the labia majora and labia minora. Frequently reported patient concerns include the presence of lumps in the vulva, discomfort, bleeding, and itching, while less common symptoms include uncomfortable urination and ulceration. Patients with vulvar malignancies may have significant delays in diagnosis owing to the absence of symptoms or the presence of non-alarming signs, such as sudden bleeding, which are more commonly observed in other types of gynecological tumors [1,15].

In this case, the patient, aged 40, had not undergone prior cervical cancer screening or exhibited abnormal skin lesions before her diagnosis of vulvar melanoma. She had given birth twice prior to the diagnosis, unlike most cases where patients are younger (average age 31 years) and often nulliparous. Vulvar melanoma has a significantly poorer prognosis, with 40% of cases diagnosed at an advanced stage [1], in contrast to other vulvar cancers, which are often detected earlier and are of lower grade. This case underscores the knowledge gap in understanding melanoma progression and recurrence during pregnancy, particularly in patients with prior full-term pregnancies [1].

Our patient had no regional lymph node metastasis, but exhibited direct expansion to adjacent organs, possibly accelerated by pregnancy. This aligns with findings of rapid tumor progression in advanced cases of invasive vulvar cancer [16]. Elevated LDH levels, as seen in our case, are associated with reduced survival in melanoma patients, indicating an advanced disease stage [1].

The physiological changes in pregnancy, including increased plasma volume and immune system alterations, likely contributed to the rapid disease progression. These changes may enhance tumor growth and spread [13]. Many international organizations recommend that women delay conception for 6–12 months after completing chemotherapy to allow for recovery and to avoid conceiving an oocyte affected by treatment [17]. However, our patient conceived within 6 months, which underscores the variability of chemotherapy’s impact on reproductive outcomes.

Surgical management was challenging due to the tumor’s progression and pregnancy. The patient underwent type IV hysterectomy, colpotomy, and bladder repair. Immunotherapy has shown promise but is limited during pregnancy due to its potential adverse effects on the fetus [18]. A multidisciplinary approach is crucial in such rare cases, with treatment tailored to both the tumor’s characteristics and the pregnancy stage.

The strength of this study lies in its focus on an extremely rare occurrence – vulvar melanoma during pregnancy – alongside a successful pregnancy outcome, which provides valuable insights into the balance of oncological treatment with pregnancy management. Given the limited cases reported, this case contributes practical guidance to the medical literature and may inform future protocols for managing similar complex cases where rapid malignancy progression coincides with pregnancy.

A limitation of this study is the inherent lack of generalizability, as our findings are based on a single patient. While the case adds to the understanding of managing such rare conditions, broader studies are needed to validate this approach. Additionally, we encountered specific challenges that influenced management, including limited standardized protocols for vulvar melanoma during pregnancy, and unique patient factors that could affect treatment tolerance and outcomes. These factors underscore the complexity of balancing treatment effectiveness with maternal-fetal safety, and similar success may not be achievable in other cases.

Conclusions

Vulvar melanoma during pregnancy is exceedingly uncommon. Pregnancy can exacerbate the proliferation and metastasis of cancer cells owing to physiological changes. This case report is an example of the rapid progression of vulvar melanoma in pregnancy that metastasized to the uterine corpus; however, it resulted in a viable live fetus. This paper reports a case of a successful pregnancy following 3 excision biopsy procedures and 6 rounds of chemotherapy. Successful conception within a year after the last administration of chemotherapy indicated that there was no exposure to chemotherapy medications during the period of conception. This report provides important clinical insights into managing a complex case involving a rapidly progressing malignancy while maintaining the safety and viability of the pregnancy.

Figures

The timeline of patient’s medical history.Figure 1.. The timeline of patient’s medical history. Biopsy specimen of the patient. (A) Biopsy result in 2020, malignant tumor cells appear solid and diffuse (black arrows), areas of necrosis and hemorrhage are visible (red arrows), magnification ×200. (B) Biopsy result in 2021, Polymorphic atypical tumor cells appear solid and diffusely arranged, some containing brown pigment (black arrow), mitotic activity is relatively high (red arrow), magnification ×400. (C) Biopsy result in 2022, invasion of pigmented malignant tumor cells is seen in the cervical connective tissue stroma (black arrow), and tumor embolism is visible in the lymphovascular space (red arrow), magnification ×200.Figure 2.. Biopsy specimen of the patient. (A) Biopsy result in 2020, malignant tumor cells appear solid and diffuse (black arrows), areas of necrosis and hemorrhage are visible (red arrows), magnification ×200. (B) Biopsy result in 2021, Polymorphic atypical tumor cells appear solid and diffusely arranged, some containing brown pigment (black arrow), mitotic activity is relatively high (red arrow), magnification ×400. (C) Biopsy result in 2022, invasion of pigmented malignant tumor cells is seen in the cervical connective tissue stroma (black arrow), and tumor embolism is visible in the lymphovascular space (red arrow), magnification ×200. Ultrasonography evaluation of the fetus shows a single live fetus equal to 27 weeks gestational age and cervical mass size 13.24×11.92×10.29 cm.Figure 3.. Ultrasonography evaluation of the fetus shows a single live fetus equal to 27 weeks gestational age and cervical mass size 13.24×11.92×10.29 cm. A mass measuring >3 cm was identified on the right labia majora on physical examination.Figure 4.. A mass measuring >3 cm was identified on the right labia majora on physical examination. Ultrasonography evaluation of the fetus shows a single live fetus equal to 28 weeks gestational age and cervical mass size 14.78×11.34×12.98 cm.Figure 5.. Ultrasonography evaluation of the fetus shows a single live fetus equal to 28 weeks gestational age and cervical mass size 14.78×11.34×12.98 cm. Documentation of surgical procedure. The right figure shows necrotic tissue that infiltrates the cervix and uterus.Figure 6.. Documentation of surgical procedure. The right figure shows necrotic tissue that infiltrates the cervix and uterus. Biopsy specimen of the tumor showing vulvar and uterine cervix specimen showing the tumor with polymorphic atypical cells, partly pigmented, solid, and diffuse in structure. Tumor cells have round, oval vesicular nuclei, prominent nucleoli, and moderate mitosis. There is visible tumor invasion between the surrounding connective tissue stroma. (A) Magnification ×100. (B) Magnification ×40.Figure 7.. Biopsy specimen of the tumor showing vulvar and uterine cervix specimen showing the tumor with polymorphic atypical cells, partly pigmented, solid, and diffuse in structure. Tumor cells have round, oval vesicular nuclei, prominent nucleoli, and moderate mitosis. There is visible tumor invasion between the surrounding connective tissue stroma. (A) Magnification ×100. (B) Magnification ×40.

References:

1.. Shindo M, Ueda Y, Kimura T, Matsuo K, Handbook of gynecology.: Handb Gynecol, 2020; 1-18

2.. Falcicchio G, Vinci L, Cicinelli E, Vulvar malignant melanoma: A narrative review: Cancers, 2022; 14(21); 5217

3.. Hiratsuka J, Kamitani N, Tanaka R, Boron neutron capture therapy for vulvar melanoma and genital extramammary Paget’s disease with curative responses.: Cancer Communications, 2018; 38(1); 38

4.. Capria A, Tahir N, Fatehi M, Vulva cancer.: StatPearls., 2024, Treasure Island (FL), StatPearls Publishing

5.. Lee YY, Roberts CL, Dobbins T, Incidence and outcomes of pregnancy-associated cancer in Australia, 1994–2008: A population-based linkage study.: BJOG, 2012; 119(13); 1572-82

6.. Still R, Brennecke S, Melanoma in pregnancy: Obstet Med, 2017; 10(3); 107-12

7.. Morgese F, Sampaolesi C, Torniai M, Gender differences and outcomes in melanoma patients: Oncol Ther, 2020; 8(1); 103-14

8.. Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V, Primary mucosal melanomas: A comprehensive review: Int J Clin Exp Pathol, 2012; 5(8); 739-53

9.. Lo SN, Scolyer RA, Thompson JF, Long-term survival of patients with thin (T1) cutaneous melanomas: A breslow thickness cut point of 0.8 mm separates higher-risk and lower-risk tumors: Ann Surg Oncol, 2018; 25(4); 894-902

10.. Clayton S: Melanoma of the vulva with pregnancy, 1946, SAGE Publications

11.. Dyduch G, Jach R, Huras H, Recurrent vulvar melanoma in 35-year-old pregnant women: J Low Genit Tract Dis, 2013; 17(2); 223-25

12.. Munemura M, Inoue S, Rin Y, Fukuda S, Primary malignant melanoma of the vulva associated with pregnancy: Clinical, light and electron microscopic observations: Nihon Sanka Fujinka Gakkai Zasshi, 1983; 35(12); 2404-8

13.. Yang X-H, Wang Y, Zhang W, Primary vulvar melanoma in a 27-year-old pregnant woman: A case report and literature review: International Journal of Dermatology and Venereology, 2019; 2(1); 47-50

14.. Todd SP, Driscoll MS, Prognosis for women diagnosed with melanoma during, before, or after pregnancy: Weighing the evidence: Int J Womens Dermatol, 2017; 3(1); 26-29

15.. Hartnett KP, Mertens AC, Kramer MR, Pregnancy after cancer: Does timing of conception affect infant health?: Cancer, 2018; 124(22); 4401-7

16.. Albert A, Lee A, Allbright R, Vijayakumar S, Vulvar melanoma: An analysis of prognostic factors and treatment patterns: J Gynecol Oncol, 2020; 31(5); e66

17.. Cho H-W, Lee S, Min K-J, Advances in the treatment and prevention of chemotherapy-induced ovarian toxicity: Int J Mol Sci, 2020; 21(20); 7792

18.. Vandenbroucke T, Verheecke M, Van Calsteren K, Fetal outcome after prenatal exposure to chemotherapy and mechanisms of teratogenicity compared to alcohol and smoking: Expert Opin Drug Saf, 2014; 13(12); 1653-65

Figures

Figure 1.. The timeline of patient’s medical history.Figure 2.. Biopsy specimen of the patient. (A) Biopsy result in 2020, malignant tumor cells appear solid and diffuse (black arrows), areas of necrosis and hemorrhage are visible (red arrows), magnification ×200. (B) Biopsy result in 2021, Polymorphic atypical tumor cells appear solid and diffusely arranged, some containing brown pigment (black arrow), mitotic activity is relatively high (red arrow), magnification ×400. (C) Biopsy result in 2022, invasion of pigmented malignant tumor cells is seen in the cervical connective tissue stroma (black arrow), and tumor embolism is visible in the lymphovascular space (red arrow), magnification ×200.Figure 3.. Ultrasonography evaluation of the fetus shows a single live fetus equal to 27 weeks gestational age and cervical mass size 13.24×11.92×10.29 cm.Figure 4.. A mass measuring >3 cm was identified on the right labia majora on physical examination.Figure 5.. Ultrasonography evaluation of the fetus shows a single live fetus equal to 28 weeks gestational age and cervical mass size 14.78×11.34×12.98 cm.Figure 6.. Documentation of surgical procedure. The right figure shows necrotic tissue that infiltrates the cervix and uterus.Figure 7.. Biopsy specimen of the tumor showing vulvar and uterine cervix specimen showing the tumor with polymorphic atypical cells, partly pigmented, solid, and diffuse in structure. Tumor cells have round, oval vesicular nuclei, prominent nucleoli, and moderate mitosis. There is visible tumor invasion between the surrounding connective tissue stroma. (A) Magnification ×100. (B) Magnification ×40.

In Press

Case report  China

Neonatal Familiar Cleidocranial Dysplasia: A Case Report

Am J Case Rep In Press; DOI: 10.12659/AJCR.946322  

Case report  Japan

Acute Extensor Pollicis Longus Tendon Injury Associated with a Distal Radius Fracture: A Case Report

Am J Case Rep In Press; DOI: 10.12659/AJCR.946399  

Case report  China

Severe Neonatal Asphyxia Associated with Ureaplasma urealyticum Infection: A Case Report

Am J Case Rep In Press; DOI: 10.12659/AJCR.946249  

Case report  Malaysia

Impact of Lupus Anticoagulant on INR Using Recombinant Prothrombin Time Reagent

Am J Case Rep In Press; DOI: 10.12659/AJCR.945579  

Most Viewed Current Articles

21 Jun 2024 : Case report  China (mainland) 82,657

Intracranial Parasitic Fetus in a Living Infant: A Case Study with Surgical Intervention and Prognosis Anal...

DOI :10.12659/AJCR.944371

Am J Case Rep 2024; 25:e944371

0:00

07 Mar 2024 : Case report  USA 49,061

Neurocysticercosis Presenting as Migraine in the United States

DOI :10.12659/AJCR.943133

Am J Case Rep 2024; 25:e943133

0:00

20 Nov 2023 : Case report  Saudi Arabia 23,527

Azithromycin Treatment for Acne Vulgaris: A Case Report on the Risk of Clostridioides difficile Infection

DOI :10.12659/AJCR.941424

Am J Case Rep 2023; 24:e941424

0:00

18 Feb 2024 : Case report  Japan 22,089

A Case of Thoracic Empyema Caused by Actinomyces naeslundii

DOI :10.12659/AJCR.943030

Am J Case Rep 2024; 25:e943030

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

American Journal of Case Reports eISSN: 1941-5923
American Journal of Case Reports eISSN: 1941-5923